Hospitals in affluent areas exploit 340B drug discounts for profit

Under the federal 340B drug discount program, eligible hospitals can purchase outpatient medications at substantially reduced prices and then bill insurers, including Medicare, at standard reimbursement levels, pocketing the margin. Although the legislation intended these savings to expand services for low-income and uninsured patients, many large health systems in affluent suburbs have turned the arrangement into a profit center.

The law lacks requirements for hospitals to demonstrate that the discounts are passed on to vulnerable patients or to disclose how the resulting revenue is allocated. This regulatory gap has allowed some institutions to reap financial gains without clear benefits to the target population. Policymakers and health-care advocates are calling on Congress to restore the program’s original intent by imposing reporting and eligibility checks. They argue that tighter oversight is essential to ensure that the discounts truly support safety-net providers and the patients they serve.